首页 > 文章详情

免疫检查点抑制剂在头颈部鳞癌和皮肤鳞癌中的应用

2018年11月17日

编译：肿瘤资讯

来源：肿瘤资讯

免疫检查点抑制剂在头颈部鳞癌和皮肤鳞癌中的应用

Danny Rischin

教授

Peter MacCallum 癌症中心肿瘤科主任
澳大利亚墨尔本

免疫检查点抑制剂已被证实在多种肿瘤中有效。在本次交流中，Danny教授将会展示并讨论最新的免疫检查点抑制剂应用于头颈部鳞癌和皮肤鳞癌有关数据。

来自一项II期研究和一项I期研究的扩展队列数据显示，在复发/转移的皮肤鳞癌中，cemiplimab（一种PD-1抑制剂）可以达到50%的客观缓解率；这种缓解不仅迅速而且持久。在这些结果的基础上，cemiplimab最近已经被FDA批准用于皮肤鳞癌。在头颈部鳞癌方面，Danny教授将会给我们展示KEYNOTE-048研究的前期结果。KEYNOTE-048是一项针对复发/转移头颈部鳞癌患者的III期试验，对比一线接受pembrolizumab单药、pembrolizumab+化疗（PF方案）、Extreme方案（PF+西妥昔单抗）的效果。结果显示pembrolizumab组均优于Extreme方案。该结果有望改写当前治疗模式。

Emerging role of immune checkpoint inhibitors in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma

Immune checkpoint inhibitors have had a profound impact on the management and treatment outcomes for many malignancies. In this presentation, Prof. Danny will discuss the emerging data in two malignancies: head and neck squamous cell carcinoma (HNSCC) which includes oral cavity, oropharynx, larynx and hypopharynx primary sites and cutaneous squamous cell carcinoma (cSCC) which predominantly arises in the head and neck.

In a phase 2 trial as well as expansion cohorts of the phase I trial, cemiplimab had remarkable activity with a 50% objective response rate in recurrent/metastasis cSCC. The responses were rapid and durable. On the basis of these results cemiplimab was recently approved by the FDA for cSCC. For HNSCC, preliminary results of KEYNOTE-048 were presented for a randomised trial in the first-line R/M setting that investigated pembrolizumab alone and pembrolizumab + chemotherapy (platinum+5FU) both compared to the Extreme regimen (platinum/5FU + cetuximab). Results showed that pembrolizumab alone or pembrolizumab + chemotherapy was superior to Extreme. These results will lead to a change in current treatment paradigms.